Skinvisible's Patent Portfolio Expands to Cover Cationic Actives
28 Mayo 2014 - 8:05AM
Marketwired
Skinvisible's Patent Portfolio Expands to Cover Cationic Actives
Compositions With Imiquimod, Terbinafine, Miconazole Have Added
Protection
LAS VEGAS, NV--(Marketwired - May 28, 2014) - Skinvisible
Pharmaceuticals, Inc. (OTCQB: SKVI) a pharmaceutical research and
development company with a proprietary delivery technology trade
named Invisicare®, today announced that it has been granted a new
patent by the United States Patent and Trademark Office entitled,
"Cationic Pharmaceutically Active Ingredient Containing
Composition, and Methods for Manufacturing and Using" (Patent
#8,735,422). The patent provides formulation protection until April
2030 and covers the composition of formulations developed with
cationic actives such as imiquimod (used for certain skin cancers:
actinic keratosis (precancerous skin lesions), superficial basal
cell carcinoma (sBCC) and external genital warts), terbinafine and
miconazole (anti-fungals used to treat athletes foot, jock itch,
ringworm, and other fungal infections of the skin) in combination
with Skinvisible's proprietary polymer delivery system,
Invisicare. Additionally, Skinvisible has filed a divisional
patent application seeking further claims.
For its formulations that require FDA approval / clinical
development, the Company proposes the 505B2 process as a
cost-effective / quick to market strategy for its prescription
products such as imiquimod. The 505B2 clinical development
process is an abbreviated submission to the FDA that allows for
companies to distinguish its products and avert substitution by
generics based on benefits approved by the FDA. Skinvisible
will be seeking licensees interested in the clinical development of
both its imiquimod and terbinafine formulations for the US and
internationally.
"This is a very important patent for Skinvisible and we are
excited to receive the acknowledgment from the US Patent and
Trademark Office for this significant innovation," said Mr. Terry
Howlett, President and CEO. "Cationic actives are vital ingredients
in the treatment of many dermatology conditions in both
over-the-counter and prescription drug products." He further
stated, "This patent, along with our US and international patents
protecting our Invisicare technology, increases the value of our
formulations and therefore the Company. We are eager to
partner with a global pharmaceutical company who will take our
finished formulations like imiquimod and other actives through the
505B2 clinical process."
Skinvisible's research and development is focused on its core
technology Invisicare; a patented topical drug delivery system
which is the foundation of all of the forty-plus products developed
at Skinvisible. Along with the new cationic patent,
Skinvisible has been granted patents for stabilizing UVA
sunscreens, retinoic acid and for dermal barrier products plus
fifteen US and international patents on Invisicare. The Company's
clinical development and commercialization strategy involves
out-licensing these formulations on an exclusive basis for
prescription and over-the-counter indications to global
pharmaceutical and consumer goods companies.
About Skinvisible
Pharmaceuticals, Inc Skinvisible Pharmaceuticals is a
research-and-development company that licenses its proprietary
formulations made with Invisicare, its patented polymer delivery
system that offers life-cycle management and unique enhancements
for topically delivered products. Invisicare holds active
ingredients on the skin for extended periods of time resisting both
wash off and perspiration along with controlling the release of
actives and reducing irritation. Skinvisible receives a combination
of research and development fees, upfront license fees, and ongoing
royalties for the life of the Invisicare patent. Skinvisible's
value also lies in its ability to continually generate new IP on
topical products formulated with
Invisicare. www.skinvisible.com and
www.invisicare.com.
Forward-Looking
Statements: This press release contains 'forward
looking' statements within the meaning of Section 21A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending March 31, 2014).
Corporate Contact: Doreen McMorran Skinvisible Pharmaceuticals,
Inc. Phone: 702-433-7154 Email:
info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024